Fibroblast Growth Factor 23 (FGF23) is a hormone involved in phosphate metabolism. It is known that FGF23 is increased in different pathologies including chronic kidney disease, heart failure or Xlinked hypophosphatemia and directly correlates with negative outcome and mortality in severe diseases. However, the role of FGF23 in cardiovascular pathologies is still under debate. This review summarizes the current knowledge about the role of FGF23 in ischemic heart diseases, such as myocardial infarction.
Introduction
Despite a significant progress in diagnostics and therapeutic strategies, ischemic heart disease is still the leading cause of death worldwide according to the World Health Association 1 . Myocardial infarction is the most feared complication of ischemic heart disease. It occurs when blood flow to the cardiac muscle decreases or is stopped 2 . The occlusion of a coronary artery is mostly caused by the rupture of an atherosclerotic plaque 2 . The following mismatch between oxygen demand and supply leads to the death of cardiomyocytes 2 . After myocardial infarction complex healing processes lead to the formation of a scar tissue, and eventually to heart failure [3] [4] [5] . The inflammatory phase with abundant infiltration of neutrophils and macrophages is followed by a proliferative phase with formation of extracellular matrix by myofibroblasts and neoangiogenesis [3] [4] [5] . Imbalance in the healing processes can lead to fibrosis, heart failure or ventricular rupture [3] [4] [5] . There are many factors involved in the regulation of these processes. Interestingly, Fibroblast Growth Factor 23 (FGF23) was shown by several studies to be a positive predictor for mortality or cardiovascular complications in heart failure, chronic kidney disease and sepsis [6] [7] [8] [9] [10] .
Fibroblast Growth Factor 23 (FGF23) is a hormone mainly produced in osteocytes. It increases renal phosphate excretion 11 . Further it decreases calcitriol and parathormone synthesis 11 . The main stimulators of FGF23 synthesis are phosphorus load and active vitamin D 12, 13 . Additionally, other factors such as calcium, iron, parathormone and inflammation influence the FGF23 synthesis 14 . FGF23 is increased in different pathologies including chronic kidney disease, heart failure or Xlinked hypophosphatemia 6, 15, 16 . Actually, many studies show a positive correlation between high amounts of FGF23 in serum and negative outcome and mortality in severe diseases 6, 8, 17, 18 . FGF23 seems to be a positive predictor for mortality or cardiovascular complications in chronic kidney disease, heart failure and sepsis 6, 7, 9, 10 .
During chronic kidney disease the amount of FGF23 in serum is increased up to 1000 fold compared to normal 15 . It is due to the high phosphorus load and has the goal to increase the phosphate excretion 19 . Further this leads to vitamin D and calcium deficiency 20 and consequent to renal osteodystrophy. During chronic kidney disease, FGF23 is upregulated in osteocytes and released into blood. Several studies showed that increased serum FGF23 during chronic kidney disease is a reliable prognostic marker 9, 18 . FGF23 positively correlates with outcome and cardiovascular mortality 9 .
FGF23 is less studied in cardiovascular pathologies. It is known from experimental studies that chronically increased FGF23 is able to induce pathological left ventricular hypertrophy 21 . FGF23 increases the calcium influx and contractility of cardiomyocytes in vitro, leading to cardiomyocyte hypertrophy 22, 23 . New studies showed that FGF23 is increased during heart failure and correlates with cardiac complications and mortality 6, 10 . Actually, different clinical studies are investigating if FGF23 is a reliable prognostic marker in heart failure ( Table 1 shows a summary of the ongoing studies). Thus, this review aims to summarize the current knowledge about FGF23 in myocardial infarction. 
FGF23 in myocardial infarction
The role of FGF23 in myocardial infarction is not clear. While it is believed that FGF23 source are osteocytes 11 , our new study showed that FGF23 is also produced in cardiac fibroblasts following myocardial infarction 24 . It seems that cardiac fibroblasts produce FGF23 during the inflammatory phase through stimulation with Il-6 (Interleukin 6), Il-1ß (Interleukin 1ß) and TNF-α (Tumor Necrosis Factor α) , whereas TGF-ß (Transforming Growth Factor ß) inhibits the expression of FGF23 later during the proliferative phase 24 . This suggests that FGF23 could potentially play a major role in healing after myocardial infarction. Indeed, our group and others could identify potential roles of FGF23 during myocardial infarction. On one hand FGF23 increases calcium influx in cardiomyocytes 23 , which leads to increased myocardial contractility and hypertrophy 22, 23 . In that way, local FGF23 possibly helps to transiently compensate the loss of contractile tissue from the infarcted area through increased contractility of the remote area after myocardial infarction. On the other hand, FGF23 seems to increase migration and proliferation of fibroblasts 24, 25 , which are responsible for preserving the mechanical tissue integrity and scar formation. FGF23 increases the expression of profibrotic genes such as collagen or TGF-ß 24, 25 . Figure 1 gives an overview of the FGF23 model of action in
Figure 1: Overview of the FGF23 model of action in myocardial infarction
During the inflammatory phase following myocardial infarction, IL-1ß, IL-6 and TNF-α increase the expression of FGF23. FGF23 leads to increased migration and proliferation of myofibroblasts and increases the expression of TGF-ß1, collagen and MMPs, but also expression of periostin and MMP8. Interestingly, periostin and MMP8 seem to be markers for heart failure and cardiac remodelling. While FGF23 induces the production of TGF-ß1, the increase of TGF-ß1 at the end of the inflammatory phase decreases the FGF23 expression, probably in a negative feedback mechanism. Longer or chronic increases of FGF23 after myocardial infarction could lead to fibrosis, left ventricular hypertrophy through increase of calcium influx and increased contractility of cardiomyocytes.
KEY POINTS ◊ Cardiac FGF23 expression increases directly after myocardial infarction, potentially promoting the (1) proliferation and migration of cardiac myofibroblasts, and (2) calcium influx, contractility and hypertrophy of cardiomyocytes

◊ Effects of FGF23 are mediated through FGFR4 (hypertrophy) and FGFR1c (fibrosis)
◊ TGF-ß decreases the expression of cardiac FGF23 myocardial infarction. Clear clinical evidence concerning the role of FGF23 during myocardial infarction is lacking. Still, a small study showed an increase of FGF23 in serum after myocardial infarction 26 . Furthermore, FGF23 significantly up-regulates factors that have been shown to be heart failure biomarkers or marker for cardiac remodelling, such as periostin and MMP8 (Matrix Metalloproteinase 8) 24, [27] [28] [29] . However, the meaning of these findings remains unclear.
FGFR1c (Fibroblast Growth Factor Receptor 1c) and FGFR4 (Fibroblast Growth Factor Receptor 4) are the most abundant receptors for FGF23 in heart 24, 30 . FGFR4 is well-known to mediate the hypertrophic effects of FGF23 on cardiomyocyte 30 , whereas FGFR1c probably mediates the profibrotic effects on myofibroblasts and macrophages 24 . However, the exact mechanisms remain to be elucidated.
Conclusion and perspective
These new data showing a cardiac expression of FGF23 during myocardial infarction opens new fields of investigation. First of all, more studies are needed to clarify the exact role of FGF23 during myocardial infarction in vivo. It is crucial to determine whether or not FGF23 is a potential target to improve cardiac function and healing after myocardial infarction. Whereas chronically high FGF23 in chronic kidney disease is detrimental, acute elevation of FGF23 in myocardial infarction might be beneficial. Since FGF23 knockout mice are not suitable for myocardial infarction experiments due to the increased weakness and sick phenotype, other experiments are needed. Conditional gene knockouts or antibody therapies could be a possibility to elucidate the exact role of FGF23. Moreover, FGF23 in serum might be a reliable marker to predict the outcome after myocardial infarction. Finally, we should investigate the role of cardiac FGF23 in other cardiac diseases such as heart failure. In conclusion, cardiac FGF23 represents a promising new field of research.
